JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online July 13, 2007, 10.2967/jnumed.107.041905
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.107.041905v1
48/8/1279    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Costes, N.
Right arrow Articles by Le Bars, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Costes, N.
Right arrow Articles by Le Bars, D.
Journal of Nuclear Medicine Vol. 48 No. 8 1279-1288
© 2007 by Society of Nuclear Medicine
doi: 10.2967/jnumed.107.041905

Clinical Investigation

Test–Retest Reproducibility of 18F-MPPF PET in Healthy Humans: A Reliability Study

Nicolas Costes1,2, Luc Zimmer1,3,4, Anthonin Reilhac1, Franck Lavenne1, Philippe Ryvlin2,3 and Didier Le Bars1

1 CERMEP–Imagerie du vivant, PET Department, Lyon, France; 2 INSERM, U821 University of Lyon 1, Lyon, France; 3 IFNL, Federative Institute of Neuroscience, Lyon, France; and 4 FRE CNRS 3006, University of Lyon 1, Lyon, France

Correspondence: For correspondence or reprints contact: Nicolas Costes, MSc, CERMEP, 59 boulevard Pinel, 69677 BRON Cedex, France. E-mail: costes{at}cermep.fr

The aim of this study was to assess the reliability of 2'-methoxyphenyl-(N-2'-pyridinyl)-p-18F-fluoro-benzamidoethylpiperazine (18F-MPPF) PET binding parameter's quantification via a test–retest study over a long-term period. Methods: Ten healthy volunteers underwent 2 dynamic 18F-MPPF PET scans in an interval of 6 mo. As a methodologic control, 10 simulated datasets, including interindividual functional and anatomic variabilities, were also used to assess the measurement variations in the absence of intraindividual variability. Indices of tracer binding were computed using 2 different models: (a) the simplified reference tissue model (SRTM) and (b) the Logan graphical model. The SRTM allows computing the binding potential (BP) index and plasma-to-brain transport constants (R1, k2). The Logan model evaluates the distribution volume (DV). For both methods, cerebellum was taken as the reference region. From both models, binding indices were calculated with time–activity curves extracted from regions of interest, on one hand, and for each voxel to perform parametric images on the other hand. Results: Reliability indices—that is, bias, variability, and intraclass correlation (ICC)—indicated a good reproducibility: the BP percentage change in mean between test and retest is close to 1% in rich regions and 2% in poor regions. The typical error is around 7%. Mean ICC is over 0.70. The DV percentage change in the mean is ±2.5%, with a typical error close to 6% and an ICC over 0.60. Conclusion: Our results show a good reliability, with a reasonable level of intraindividual biologic variability that allows crossover studies with 18F-MPPF in which small percentage changes are expected between test and retest measurements, in group studies and for single subject assessment.

Key Words: PET • serotonin 5-HT1A receptors • test–retest study • reliability • 18F-MPPF

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2007 48: 11a-12a. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2007 by the Society of Nuclear Medicine.